Gregory Piazza on CORONA-VTE Network Analysis
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, shared on LinkedIn:
”Almost 6 years out from the start of the COVID-19 pandemic and we’re still learning a lot!
Great effort from our CORONA-VTE Network showing that our oncology patients with active cancer bear added risk for thrombosis when infected with SARS-CoV-2.”
Read the full article here.
Article: Association between Active Cancer and Risk of Thrombotic and Cardiovascular Outcomes in Outpatients with COVID-19: A CORONA-VTE Network Analysis
Authors: Bridget McGonagle, Christie Greason, Darsiya Krishnathasan, Giovanni Scimeca, Antoine Bejjani, Candrika D. Khairani, Nada Hamade, Alyssa Sato, Hannah Leyva, Umberto Campia, Julia Davies, Nicole Porio, Ali A. Assi, Andre Armero, Anthony Tristani, Marcos D. Ortiz-Rios, Victor Nauffal, Zaid Almarzooq, Eric Wei, Valeria Zuluaga-Sánchez, Mehrdad Zarghami, Aditya Achanta, Sirus J. Jesudasen, Bruce C. Tiu, Geno J. Merli, Orly Leiva, John Fanikos, Aditya Sharma, Samantha Rizzo, Mariana B. Pfeferman, Ruth B. Morrison, Alec Vishnevsky, Judith Hsia, Mark R. Nehler, James Welker, Marc P. Bonaca, Brett J. Carroll, Samuel Z. Goldhaber, Zhou Lan, Behnood Bikdeli, Gregory Piazza
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show